Sebastian Neuber
Overview
Explore the profile of Sebastian Neuber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roesel M, Nersesian G, Neuber S, Thau H, von Gudenberg R, Lanmueller P, et al.
Rev Cardiovasc Med
. 2024 Jul;
25(5):176.
PMID: 39076481
Heart failure (HF) is a common disease associated with high morbidity and mortality rates despite advanced pharmacological therapies. Heart transplantation remains the gold standard therapy for end-stage heart failure; however,...
2.
Thau H, Neuber S, Emmert M, Nazari-Shafti T
Cardiol Ther
. 2024 Feb;
13(1):39-67.
PMID: 38381282
Numerous genetic and epidemiologic studies have demonstrated an association between elevated levels of lipoprotein(a) (Lp[a]) and cardiovascular disease. As a result, lowering Lp(a) levels is widely recognized as a promising...
3.
Emmert M, Burrello J, Wolint P, Hilbe M, Andriolo G, Balbi C, et al.
Eur Heart J
. 2023 Oct;
45(9):728-732.
PMID: 37787585
No abstract available.
4.
Nazari-Shafti T, Thau H, Zacharova E, Beez C, Exarchos V, Neuber S, et al.
Eur J Cardiothorac Surg
. 2023 Sep;
64(6).
PMID: 37740952
Objectives: Despite the success of coronary artery bypass graft (CABG) surgery using autologous saphenous vein grafts (SVGs), nearly 50% of patients experience vein graft disease within 10 years of surgery....
5.
Treatment of Cardiac Fibrosis with Extracellular Vesicles: What Is Missing for Clinical Translation?
Neuber S, Ermer M, Emmert M, Nazari-Shafti T
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37445658
Heart failure is the leading cause of morbidity and mortality and currently affects more than 60 million people worldwide. A key feature in the pathogenesis of almost all forms of...
6.
Liu Z, Neuber S, Klose K, Jiang M, Kelle S, Zhou N, et al.
J Cardiovasc Med (Hagerstown)
. 2023 Mar;
24(4):244-252.
PMID: 36938808
Background And Aims: High epicardial adipose tissue (EAT) attenuation is a key characteristic of adipose tissue dysfunction and associated with coronary artery disease (CAD). As little is known about the...
7.
Exarchos V, Neuber S, Meyborg H, Giampietro C, Chala N, Moimas S, et al.
Front Cardiovasc Med
. 2022 Oct;
9:953582.
PMID: 36277782
Thrombogenicity remains a major issue in cardiovascular implants (CVIs). Complete surficial coverage of CVIs by a monolayer of endothelial cells (ECs) prior to implantation represents a promising strategy but is...
8.
Exarchos V, Zacharova E, Neuber S, Giampietro C, Motta S, Hinkov H, et al.
Front Cardiovasc Med
. 2022 Oct;
9:971028.
PMID: 36186971
Cardiovascular (CV) implants are still associated with thrombogenicity due to insufficient hemocompatibility. Endothelialization of their luminal surface is a promising strategy to increase their hemocompatibility. In this review, we provide...
9.
Duran A, Schwestka M, Nazari-Shafti T, Neuber S, Stamm C, Gossen M
ACS Synth Biol
. 2022 Jul;
11(8):2623-2635.
PMID: 35815862
MicroRNAs play an essential role in cell homeostasis and have been proposed as therapeutic agents. One strategy to deliver microRNAs is to genetically engineer target cells to express microRNAs of...
10.
Xu Z, Neuber S, Nazari-Shafti T, Liu Z, Dong F, Stamm C
PLoS One
. 2022 Jan;
17(1):e0261462.
PMID: 34986181
Background: Cell-based therapy has long been considered a promising strategy for the treatment of heart failure (HF). However, its effectiveness in the clinical setting is now doubted. Because previous meta-analyses...